From: Potential immunomodulatory effects of latent toxoplasmosis in humans
Age P | Sex P | Toxo P | sex-toxo P | women-neg mean | women-pos mean | men-neg mean | men-pos mean | |
---|---|---|---|---|---|---|---|---|
all immunology outpatients N = 440 | ||||||||
CD3 (× 106/L) | 0.000* | 0.009* | 0.599 | 0.164 | 1549.190 | 1507.236 | 1481.540 | 1190.571 |
CD19 (× 106/L) | 0.000* | 0.002* | 0.045* | 0.012* | 254.091 | 224.514 | 262.205 | 155.143 |
CD4 (× 106/L) | 0.000* | 0.000* | 0.474 | 0.149 | 989.026 | 977.625 | 878.469 | 722.786 |
CD8 (× 106/L) | 0.000* | 0.395 | 0.974 | 0.439 | 512.725 | 490.028 | 527.973 | 431.429 |
CD16 + 56 (× 106/L) | 0.709 | 0.861 | 0.508 | 0.016* | 215.268 | 243.722 | 257.795 | 208.857 |
CD4/CD8 | 0.001* | 0.021* | 0.835 | 0.875 | 2.162 | 2.211 | 1.809 | 2.020 |
patients with allergies, seasonal allergic rhinitis and asthma J.30.1-4, N = 117 | ||||||||
CD3 (× 106/L) | 0.002* | 0.291 | 0.990 | 0.920 | 1566.797 | 1444.375 | 1544.031 | 1331.600 |
CD19 (× 106/L) | 0.000* | 0.852 | 0.723 | 0.208 | 223.625 | 232.063 | 279.469 | 205.200 |
CD4 (× 106/L) | 0.026* | 0.121 | 0.621 | 0.731 | 979.719 | 930.875 | 855.938 | 839.000 |
CD8 (× 106/L) | 0.074 | 0.704 | 0.549 | 0.856 | 532.062 | 443.125 | 574.125 | 491.000 |
CD16 + 56 (× 106/L) | 0.180 | 0.913 | 0.866 | 0.032* | 223.652 | 319.500 | 283.788 | 236.000 |
CD4/CD8 | 0.011* | 0.727 | 0.648 | 0.400 | 2.069 | 2.174 | 1.661 | 2.222 |
patients with immunodeficiencies, D89.9, N = 250 | ||||||||
CD3 (× 106/L) | 0.000* | 0.077 | 0.423 | 0.112 | 1479.986 | 1509.234 | 1481.694 | 1105.000 |
CD19 (× 106/L) | 0.000* | 0.141 | 0.116 | 0.210 | 249.216 | 220.213 | 251.613 | 128.143 |
CD4 (× 106/L) | 0.065 | 0.007* | 0.251 | 0.089 | 950.075 | 972.426 | 884.903 | 635.000 |
CD8 (× 106/L) | 0.000* | 0.829 | 0.877 | 0.299 | 486.552 | 505.149 | 534.807 | 419.429 |
CD16 + 56 (× 106/L) | 0.992 | 0.875 | 0.271 | 0.161 | 211.745 | 218.851 | 250.985 | 187.571 |
CD4/CD8 | 0.000* | 0.023 | 0.463 | 0.570 | 2.176 | 2.232 | 1.816 | 1.792 |